Jeff Aronin is passionate about science and is driven to build great companies that can have a positive impact on the healthcare industry. For over two decades he has been working to build biotech and healthcare companies that create medicines that improve people’s lives. Aronin founded Ovation Pharmaceuticals in 2000 and served as its president and CEO for 9 years. When it was purchased by Lundbeck Incorporated for $900 million, Aronin was Lundbeck’s president and CEO for a year. In 2012, Jeff Aronin started his second company. The company develops, manufactures and markets pharmaceutical products for patients with rare diseases.

Part of the reason Jeff Aronin is so driven to produce pharmaceutical products is because early in his career he shadowed a doctor working with seriously ill patients. Aronin saw instances where the right drug could save a patient’s life without them having to endure major surgery. That taught him the power pharmaceutical products had to help people and inspired him to use his time and energy to developing companies that create products to help the sick.

For the past 81/2 years Jeff Aronin has been chairman and CEO of both Paragon Pharmaceutical Capital and Paragon Biosciences, LLC. Paragon Pharmaceutical Capital is a global firm that establishes, invests in, develops and fosters the growth of life science and biopharmaceutical companies. Paragon Biosciences builds innovative biotechnology companies that produce important medicines to treat debilitating diseases that cause human suffering. Through their expertise and entrepreneurial experience Paragon Biosciences has helped accelerate the advancement and secured FDA approvals for 13 drugs.

Jeff Aronin has been on the board of directors of Discover Financial Services since the middle of 2007. Aronin has the ability to help companies quickly become successful in their quest to bring new medicines to patients that need them. He has continually demonstrated the value of the development and marketing strategies he created. They are rooted in an understanding of the needs of patients, his talent for identifying promising emerging science, as well as his ability to get his team to focus on getting the necessary medicines approved.